IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
6
Bullish
6
Bearish
6
Neutral
6
Bullish
34
Bearish
4
Neutral
0
Bullish
28
Bearish
4
Neutral
0
Bullish
28
Bearish
4
Neutral
0
Bullish
28
Bearish
4
Neutral
0
Bullish
28
Beryl Drugs Limited manufactures, sells and exports branded and generic pharmaceutical formulations, focusing on small- and large-volume injectables, I.V. fluids, eye/ear drops, veterinary products and contract manufacturing services produced at WHO‑GMP compliant facilities based in Indore, India, serving domestic and international customers through its sales and distribution network and an R&D capability supporting formulation development and CMOs.
The company reported total revenue from operations of Rs. 756.63 lakhs for the quarter ended 30 June 2026, with profit before tax of Rs. 26.98 lakhs and net profit of Rs. 22.08 lakhs; revenue improved materially year‑on‑year from Rs. 283.58 lakhs but operating profitability declined significantly versus the preceding quarter when PBT was Rs. 86.58 lakhs.
Beryl’s manufacturing units are stated to comply with WHO‑GMP standards and the company holds ISO 9001:2000 certification, positioning it to serve regulated buyers and contract manufacturing clients; the company reports a single operating segment—’Pharmaceutical Industry’—and highlights both branded product lines and contract manufacturing as core revenue drivers.
Key near‑term issues include thin absolute profits, quarter‑to‑quarter volatility in inventory and employee costs, and limited public disclosures on capex or strategic investments; conversely, the company can pursue higher utilisation, expand contract manufacturing and export channels leveraging WHO‑GMP compliance to scale margins and spread fixed costs across higher volumes.
Pharmaceuticals & Biotechnology
Pharmaceuticals
13 Cr
Low Risk
20.7
39.5
0.1
1.3
29.90
15.92
Sales CAGR
Profit CAGR
ROE
ROCE
Upcoming Result Date: Nov 13, 2026
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q3 FY25
Beryl Drugs Ltd (BERLDRG) is currently trading at 25.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Beryl Drugs Limited manufactures, sells and exports branded and generic pharmaceutical formulations, focusing on small- and large-volume injectables, I.V. fluids, eye/ear drops, veterinary products and contract manufacturing services produced at WHO‑GMP compliant facilities based in Indore, India, serving domestic and international customers through its sales and distribution network and an R&D capability supporting formulation development and CMOs. The company reported total revenue from operations of Rs. 756.63 lakhs for the quarter ended 30 June 2026, with profit before tax of Rs. 26.98 lakhs and net profit of Rs. 22.08 lakhs; revenue improved materially year‑on‑year from Rs. 283.58 lakhs but operating profitability declined significantly versus the preceding quarter when PBT was Rs. 86.58 lakhs. Beryl’s manufacturing units are stated to comply with WHO‑GMP standards and the company holds ISO 9001:2000 certification, positioning it to serve regulated buyers and contract manufacturing clients; the company reports a single operating segment—’Pharmaceutical Industry’—and highlights both branded product lines and contract manufacturing as core revenue drivers. Key near‑term issues include thin absolute profits, quarter‑to‑quarter volatility in inventory and employee costs, and limited public disclosures on capex or strategic investments; conversely, the company can pursue higher utilisation, expand contract manufacturing and export channels leveraging WHO‑GMP compliance to scale margins and spread fixed costs across higher volumes.
Over the past 52 weeks, Beryl Drugs Ltd has traded between a low of ₹15.92 and a high of ₹29.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Beryl Drugs Ltd has a market capitalization of approximately 12.85. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Beryl Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.73 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 12.85 Cr, Beryl Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Beryl Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Beryl Drugs Ltd is 20.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
36.00 | 15 Cr | 4.15 | 0.76 | 0.00 | 20.15 | 30.12 | 10.11 | ||
38.00 | 15 Cr | 9.49 | 0.88 | 0.00 | 9.36 | 11.66 | 3.86 | ||
24.50 | 14 Cr | 25.38 | 1.07 | 0.00 | 4.23 | 5.80 | 2.63 | ||
25.34 | 13 Cr | 20.73 | 1.30 | 0.00 | 4.30 | 7.56 | 4.14 | ||
28.25 | 13 Cr | 74.47 | 2.81 | 0.00 | 3.63 | 9.31 | 2.70 | ||
14.49 | 12 Cr | -17.58 | 9.52 | 0.00 | -59.85 | -32.17 | -19.35 | ||
4.26 | 11 Cr | 5.14 | 0.18 | 0.00 | 4.22 | 6.63 | 1.28 | ||
| Median: 7 Co. | — | 25.34 | 13 Cr | 9.49 | 1.07 | 0.00 | 4.23 | 7.56 | 2.70 |
